CellPryme-M question, page-29

First 29 Last

Share
Profile

Follow
Shellbell

7,702 Posts.

3260

14/06/22

13:50

Post #: 61991090
Share
Originally posted by hottod: ↑

On the subject of enhancing CAR-T cell activity by editing PD-1, California-based Caribou Biosciences has recently reported results from a Phase 1 study in relapsed or refractory B cell non-Hodgkin lymphoma.

Caribou’s trial is the first to use PD-1 editing in allogeneic CAR-T to enhance persistence by preventing rejection or rapid exhaustion of the cells.

Initial trial data, reported last month, looked spectacular. Following a single dose of 40 million CAR-T cells, 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) was achieved.

However, reporting this month of 6 month results has revealed that just 40% of patients remained in CR (2 of 5 patients), raising questions about the success of Caribou’s approach in tackling the issue of durability, which has been a widespread issue for developers of allogeneic CAR-Ts.

Caribou will now double its dose and results are worthwhile keeping an eye on.

Prescient’s OmniCAR, which can be used with allogeneic CAR-T, and its CellPryme M and CellPryme A platforms all address the challenge of cell persistence.

https://www.cariboubio.com/

https://www.fiercebiotech.com/biote...t-hit-durability-doubts-half-patients-relapse

CRISPR Therapeutics has reported initial data from its Phase I study of CTX130, an allogeneic CAR-T cell therapy, in patients with peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

At the data cut off point, the trial had 19 patients enrolled - 8 with peripheral T-cell lymphoma and 10 with cutaneous T-cell lymphoma. All patients and had been heavily pre-treated with a median of four systemic therapies, had a median CD70 expression of 90% and were refractory up to their last therapy line.

At the third dose level and above, ORR was 70% with 30% of patients achieving a CR. In addition, 90% of patients at this level had clinical benefit defined as a stable disease or better response. ORR was 80% in PTCL and 60% in CTCL.

Another one to keep an eye on as Prescient now focuses on targeting PTCL with PTX-100 in a Phase 1b expansion cohort.

https://crisprtx.gcs-web.com/news-r...peutics-presents-positive-results-its-phase-1

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress | BioSpace

https://www.biospace.com/article/-c...rug-candidate-found-safe-in-early-data-/?s=89

Expand

Hey hottod, what I just quickly picked up in the CRISPR Therapeutics Phase I study of CTX130 is that while the results are excellent, it should be noted that patients were also receiving chemo as part of the trials.

Prescient's PTX100 equivalent (ie treating PTCL and CTCL also) precludes the use of radiation and chemo 2 weeks prior to first dose. Surely, that puts PTX100 in a superior postion? See the first three in the list:

Exclusion Criteria:
Radiation, chemotherapy, immunotherapy, or any other approved anticancer therapy ≤ 2 weeks prior to study treatment
Participation in another interventional investigational drug study within 4 weeks prior to enrollment
Concurrent radiation, chemotherapy, immunotherapy, or any other approved or investigational anticancer therapeutic (Patients are allowed to receive ≤ 10 mg/day corticosteroids for the treatment of non malignant disorders.)

https://www.clinicaltrials.gov/ct2/show/NCT03900442?term=PTX100&cond=Cancer&cntry=AU&draw=2&rank=1

Prescient has also been granted Orphan Drug Designation.

PTX is up there with its science is my take.
Last edited by Shellbell: 14/06/22

PTX Price at posting: 16.5¢ Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply